Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BFR14: Glivec Interruption vs Maintenance in Advanced GIST
NCT00367861Phase 3Completed
- Sponsor
- Centre Léon Bérard
- Start
- May 2002
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-Free Survival at 2 years. Started May 2002; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00367861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367861.